Sita Kugel

Title: Sita Kugel: Innovator in Cancer Treatment

Introduction

Sita Kugel is a prominent inventor based in Brookline, MA (US), known for her significant contributions to the field of cancer research. With a focus on pancreatic ductal adenocarcinomas (PDAC), she has developed innovative methods and agents aimed at improving treatment outcomes for this aggressive form of cancer.

Latest Patents

Sita Kugel holds 2 patents related to her groundbreaking work. Her latest patents focus on agents and methods for treating pancreatic ductal adenocarcinomas. It has been discovered that NAD-dependent histone deacetylase SIRT6 is critical for the suppression of PDAC by controlling the expression of Lin28b, a negative regulator of let-7 microRNA. Specifically, the loss of SIRT6 results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, including HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing the expression or activity of Lin28b to treat aggressive PDAC in a subject.

Career Highlights

Sita Kugel is affiliated with The General Hospital Corporation, where she continues to advance her research and innovation in cancer treatment. Her work has garnered attention for its potential to significantly impact the lives of patients suffering from pancreatic cancer.

Collaborations

Sita has collaborated with notable colleagues in her field, including Raul Mostoslavsky and Anders M Naar. These partnerships have further enriched her research and contributed to the development of her innovative treatments.

Conclusion

Sita Kugel's contributions to cancer research, particularly in the treatment of pancreatic ductal adenocarcinomas, highlight her role as a leading inventor in the medical field. Her innovative approaches and dedication to improving patient outcomes are commendable and reflect the importance of continued research in cancer treatment.